This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hu, P. Articles by Epstein, A. L. Search for Related Content PubMed PubMed Citation Articles by Hu, P. Articles by Epstein, A. L.

Comparison of Three Different Targeted Tissue Factor Fusion Proteins for Inducing Tumor Vessel Thrombosis¹

Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033

Tissue Factor (TF) is a cell membrane receptor protein that is the initiator of the extrinsic pathway of the blood coagulation cascade and normally released from damaged tissues. By substituting the attachment site with a tumor delivery agent, this potent thrombogenic protein in its truncated form (tTF) can be targeted to the tumor where it can initiate clotting, thereby occluding the tumor’s blood supply and causing rapid tumor destruction. To test the therapeutic potential of this vascular targeting approach, three fusion proteins, chTNT-3/tTF, chTV-1/tTF, and RGD/tTF, which target DNA exposed in degenerative areas of tumors, fibronectin on the tumor vascular basement membrane, and ß3 on the luminal side of tumor vessels, respectively, were developed and tested for their antitumor effects. Antigen binding and clotting assays demonstrated that each of the fusion proteins retained their antigen binding and thrombogenic activities. In vivo studies in mice bearing established MAD109 lung and Colon 26 carcinomas revealed that all three reagents induced histological evidence of microregional thrombosis and massive cell necrosis. Of interest, the chTV-1/tTF and RGD/tTF fusion proteins induced thrombosis in small and medium sized tumor vessels, whereas the chTNT-3/tTF induced clotting in relatively larger vessels. Treatment studies showed that chTNT-3/tTF and chTV-1/tTF but not RGD/tTF had a significant inhibition of tumor growth. These studies demonstrate that multiple targets exist which can be used to localize tTF to occlude tumor vessels in two diversely different murine tumor models. To attain a significant antitumor effect, however, these thrombogenic agents had to occlude medium and large vessels within the tumor. Additional studies are warranted to identify maximal conditions for inducing therapeutic vascular coagulation as a new and potent method of cancer therapy.

This article has been cited by other articles:

				M. H. A. M. Fens, E. Mastrobattista, A. M. de Graaff, F. M. Flesch, A. Ultee, J. T. Rasmussen, G. Molema, G. Storm, and R. M. Schiffelers Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells Blood, May 1, 2008; 111(9): 4542 - 4550. [Abstract] [Full Text] [PDF]

				E. K. Waters, S. Yegneswaran, and J. H. Morrissey Raising the Active Site of Factor VIIa above the Membrane Surface Reduces Its Procoagulant Activity but Not Factor VII Autoactivation J. Biol. Chem., September 8, 2006; 281(36): 26062 - 26068. [Abstract] [Full Text] [PDF]

				X. Huang, W.-Q. Ding, J. L. Vaught, R. F. Wolf, J. H. Morrissey, R. G. Harrison, and S. E. Lind A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties Blood, February 1, 2006; 107(3): 980 - 986. [Abstract] [Full Text] [PDF]

				T. Kessler, R. Bieker, T. Padro, C. Schwoppe, T. Persigehl, C. Bremer, M. Kreuter, W. E. Berdel, and R. M. Mesters Inhibition of Tumor Growth by RGD Peptide-Directed Delivery of Truncated Tissue Factor to the Tumor Vasculature Clin. Cancer Res., September 1, 2005; 11(17): 6317 - 6324. [Abstract] [Full Text] [PDF]

				M. Guba, M. Yezhelyev, M. E. Eichhorn, G. Schmid, I. Ischenko, A. Papyan, C. Graeb, H. Seeliger, E. K. Geissler, K.-W. Jauch, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF Blood, June 1, 2005; 105(11): 4463 - 4469. [Abstract] [Full Text] [PDF]

				A. Dienst, A. Grunow, M. Unruh, B. Rabausch, J. E. Nor, J. W. U. Fries, and C. Gottstein Specific Occlusion of Murine and Human Tumor Vasculature by VCAM-1-Targeted Recombinant Fusion Proteins J Natl Cancer Inst, May 18, 2005; 97(10): 733 - 747. [Abstract] [Full Text] [PDF]

				C. Liu, C. Dickinson, J. Shobe, F. Donate, W. Ruf, and T. Edgington A hybrid fibronectin motif protein as an integrin targeting selective tumor vascular thrombogen Mol. Cancer Ther., July 1, 2004; 3(7): 793 - 801. [Abstract] [Full Text] [PDF]